The first combined meta‐analytic approach for elucidating the relationship of circulating resistin levels and RETN gene polymorphisms with colorectal and breast cancer

Egyptian Journal of Medical Human Genetics

Table 1 Characteristics of the selected studies evaluating resistin level with colorectal cancer in the meta-analysis

Study ID	Country	Cases/controls	Assay type	Kit provider	Mean resistin level (ng/ml) ± SD		NOS score
Study ID	Country	Cases/controls	Assay type	Kit provider	Cases	Controls	NOS score
Serum
Al-Harithy et al. [25]	KSA	60/60	ELISA kit	ALPCO Diagnostic	19.44 ± 8.46	5.45 ± 2.73	7
Danese et al. [26]	Italy	40/40	ELISA kit	Mediagnost	9.99 ± 15.76	4.98 ± 4.92	8
Gonullu et al. [27]	Turkey	36/37	ELISA kit	BioSource	6.1 ± 3.3	4.5 ± 1.5	8
Joshi et al. [28]	South Korea	100/100	ELISA kit	Adipogen	4.9 ± 2.3	2.8 ± 1.7	8
Kosova et al. [29]	Turkey	20/20	ELISA kit	Millipore Corporation	4.92 ± 2.2	3.39 ± 1.1	7
Kumor et al. [30]	Poland	36/25	ELISA kit	R&D Systems	6.79 ± 2.41	3.6 ± 1.08	7
Lu et al. [31]	China	30/30	ELISA kit	ADL	7.72 ± 2.6	7.42 ± 3.72	7
Shafik et al. [32]	Egypt	30/25	ELISA kit	AssayMax™	18.86 ± 2.6	9.55 ± 1.4	7
Tulubas et al. [33]	Turkey	30/30	ELISA kit	AssayMax™	18.77 ± 5.09	13.36 ± 6.36	8
Total		382/367
Plasma
Farahani et al. [34]	Iran	82/88	ELISA kit	ZellBio	5.7 ± 1.2	5.4 ± 1.3	8
Hillenbrand et al. [35]	Germany	67/60	Multiplex Assay	Millipore	19.53 ± 29.58	13.63 ± 14.96	7
Ho et al. [36]	USA	456/834	Multiplex Assay	Millipore	13.03 ± 4.83	12.57 ± 4.31	8
Mihajlovic et al. [11]	Serbia	86/75	ELISA kit	R&D Systems	20.72 ± 10.62	12.08 ± 7.58	7
Nakajima et al. [37]	Japan	115/115	ELISA kit	BioVender	4.67 ± 2.48	3.33 ± 1.88	8
Wägsäter et al. [38]	Sweden	35/34	ELISA kit	R&D Systems	2.62 ± 0.70	3.42 ± 0.77	7
Zhao et al. [39]	China	358/286	ELISA kit	Biovision Inc	8.03 ± 4.99	5.69 ± 3.18	8
Total		1199/1492